Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by ...

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$ ...

By every measure, that spending is on the rise; by drug “list price,” the increase is astronomical—from $636 billion in 2018 to $917 billion in 2023. What exactly are PBMs saving us from ...

Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know about stimulant medications in ADHD. Attention Deficit Hyperactivity ...

Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...

China’s healthcare regulator has pledged to investigate the quality of drugs under a new list covered by national insurance, after policy advisers in Shanghai warned that they might be substandard.

Blockbuster obesity drugs such as Ozempic have been celebrated for their ability to promote weight loss and treat a surprising range of other conditions, from heart problems to Parkinson’s disease.

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

For example, a person might take one medication that makes them sleepy, and another pill that makes them wake up at night to urinate. That can lead them to trip and fall in the middle of the night ...

Before the advent of medications, individuals with these more extreme symptoms often found themselves stuck—unable to engage meaningfully in therapy or, in many cases, requiring long-term ...

"The $7.3 billion is the difference between what they are reimbursing themselves and what it is estimated to cost them to acquire the drug," an FTC spokesperson told reporters in a press briefing ...